Evaluating intramuscular epinephrine in pediatric out-of-hospital cardiac arrest (the PRIME trial): study protocol for a multi-centre, stepped-wedge cluster quasi-randomized controlled trial Authors: Samina Idrees, Maysaa Assaf, Matthew Davis, Facundo Garcia-Bournissen, Jay Loosley, Michael R Miller, Janice A Tijssen Published: 2026 ABSTRACT AbstractBackgroundPediatric out-of-hospital cardiac arrest (POHCA) is a time-sensitive event with a high mortality rate. Epinephrine is a key first-line medication used during cardiac arrest resuscitation to support perfusion and return of spontaneous circulation (ROSC). Guidelines for the management of POHCA recommend paramedics administer epinephrine as soon as possible by intravenous (IV) or intraosseous (IO) injection. However, successfully inserting an IV or IO line can be challenging in high-stress situations, particularly in a poorly perfused, small child. In contrast, intramuscular (IM) epinephrine, which is the standard of care in anaphylaxis management, does not require paramedics to secure vascular access and may lead to a shorter time to first dose. The POHCA Resuscitation: Evaluation of IM Epinephrine (PRIME) trial aims to evaluate the impact of IM epinephrine on POHCA outcomes. The primary objective of the PRIME trial is to determine if an initial dose of IM epinephrine improves time to return of spontaneous circulation (ROSC) compared to standard of care alone.MethodsThe PRIME trial is a prospective, multi-centre, pragmatic, two-arm, open-label, stepped-wedge cluster quasi-randomized controlled trial. We will randomize at the level of the paramedic service, as individual-level randomization is not possible due to the inclusion of multiple, heterogeneous regions. Each site will serve as its own control. This study is a regional trial, with a focus on limited efficacy testing through an intermediate outcome (i.e., time to ROSC) that is strongly associated with survival. We also aim to evaluate the impact of the intervention on survival to hospital discharge, survival to hospital discharge with favourable neurological outcome, and safety in POHCA management.DiscussionThe PRIME trial aims to provide insight into the effectiveness and safety of IM epinephrine in POHCA. The data and analyses generated from the trial have the potential to inform resuscitation guidelines and standard of care practices.Trial registrationClinicalTrials.gov NCT05166343, Registered on December 8, 2021.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13063-026-09776-3.Keywords: Pediatric out-of-hospital cardiac arrest, Resuscitation, Epinephrine, Intramuscular, ROSC, Randomized controlled trial Administrative information Title {1}Evaluating intramuscular epinephrine in pediatric out-of-hospital cardiac arrest (the PRIME trial): study protocol for a multi-centre, stepped-wedge cluster quasi-randomized controlled trialTrial registration {2a and 2b}ClinicalTrials.gov, NCT05166343, Registered on December 8, 2021World Health Organization Trial Registration Data Set (Suppl. Table 2)Protocol version {3}December 17, 2025Funding {4}Academic Medical Organization of Southwestern OntarioChildren's Health Research InstituteThe Thrasher Research FundThe Heart and Stroke Foundation of CanadaAuthor details {5a}Samina Idrees, MSc1,2; Maysaa Assaf, BSc1,2; Matthew Davis, MD, MSc3,4; Facundo Garcia-Bournissen, MD, PhD5; Jay Loosley, RN, ACP, BEd6; Michael R. Miller, PhD1,7; Janice A. Tijssen, MD, MSc1,2,7Name and contact information for the trial sponsor {5b}London Health Sciences Centre Research Institute800 Commissioners Rd ELondon, ONN6A 5W9Role of sponsor {5c}The study sponsor and funders had no role in the design or conduct of the study, including the decision to submit the manuscript for publication ClinicalTrials.gov, NCT05166343, Registered on December 8, 2021 World Health Organization Trial Registration Data Set (Suppl. Table 2) Academic Medical Organization of Southwestern Ontario Children's Health Research Institute The Thrasher Research Fund The Heart and Stroke Foundation of Canada London Health Sciences Centre Research Institute 800 Commissioners Rd E London, ON N6A 5W9 Introduction Background and rationale {6a} Pediatric out-of-hospital cardiac arrest (POHCA) occurs when a child experiences a sudden loss of circulation in an out-of-hospital setting. POHCA is associated with significant mortality, with only 2-10% of children surviving to hospital discharge [1–10]. The quality of life for many survivors is poor, with up to 30% experiencing new and significant neurological impairments post-arrest [11]. There are several factors that can impact the likelihood of survival with neurologically favourable outcomes, including bystander cardiopulmonary resuscitation (CPR), automated external defibrillator (AED) application, and emergency medical services (EMS) response times [12–14]. The timely arrival of EMS and early on-scene management of POHCA, including early epinephrine administration and optimal time spent on scene have been associated with improved survival outcomes [8, 15]. Epinephrine is a key first-line medication used during cardiac arrest resuscitation to support perfusion and return of spontaneous circulation (ROSC). As an adrenergic agent and cardiac stimulant, it increases blood pressure by (1) stimulating cardiac muscle and increasing the strength of ventricular contractions; (2) increasing heart rate; and (3) constricting arterioles [16, 17]. The Pediatric Advanced Life Support (PALS) guidelines recommend epinephrine be administered to POHCA patients in doses of 0.01 mg/kg by intravenous (IV) or intraosseous (IO) injection, where the initial dose should be administered as soon as possible, with subsequent doses every 3 to 5 min [18]. Previous research has found an association between delays in the administration of the first epinephrine dose and poor survival outcomes among cardiac arrest patients [19–21]. In a recent local retrospective study, we found that 84% of POHCA patients had their first epinephrine dose more than 5 min after the arrival of EMS, and 29% after 10 min [22]. Sixty-seven percent of the delays could be attributed to a delay in obtaining IV/IO access. This inability to meet guidelines has been described across other jurisdictions [19–21]. In our local sample, only 6% survived to hospital discharge. Successfully inserting an IV or IO line can be challenging in high-stress situations, particularly in a poorly perfused, small child. Additionally, IV and IO epinephrine delivery is outside the scope of practice for many paramedics, whereas most are already trained and authorized to administer intramuscular (IM) epinephrine for anaphylaxis. IM epinephrine is the standard of care in anaphylaxis management [23, 24], and it is widely recognized as a safe and rapid route of administration [25], requiring minimal training and potentially a shorter time to administration relative to IV or IO routes. However, findings from separate pharmacokinetic studies indicates that the bioavailability and time to peak blood concentration for IM epinephrine is inferior to IV and IO epinephrine [26–30]. Direct head-to-head comparisons between IM and IV or IO epinephrine remain limited. In a study of cardiac arrest rat models, Lim et al. (2021) found that IM epinephrine improved ROSC rates relative to placebo, but not relative to IV epinephrine [31]. Mauch et al. (2013) found that IM epinephrine improved ROSC rates relative to delayed IV epinephrine, but not early IV epinephrine in porcine models [32]. O’Reilly et al. (2024) found comparable time to ROSC between IM and IV epinephrine in pediatric porcine cardiac arrest models [33]. Recent data indicate that IM epinephrine is feasible for treating out-of-hospital cardiac arrest (OHCA) in adults, and may be associated with improved survival to hospital discharge and favorable neurologic status [34, 35]. However, these data may not reflect the impact of IM epinephrine in pediatric populations. The POHCA Resuscitation: Evaluation of IM Epinephrine (PRIME) trial aims to evaluate the impact of IM epinephrine on POHCA outcomes. Objectives {7} The primary objective of the PRIME trial is to determine if an initial dose of IM epinephrine (followed by standard of care) improves time to ROSC compared to standard of care alone. We also aim to evaluate the impact of IM epinephrine on survival to hospital discharge, survival to hospital discharge with favourable neurological outcome, and safety in POHCA management. Trial design {8} The PRIME Trial is a prospective, multi-centre, pragmatic, two-arm, open-label, stepped-wedge cluster quasi-randomized controlled trial (SW-CRCT). This trial includes multiple paramedic services across Ontario, Canada. The SW-CRCT design is indicated as IM epinephrine may be beneficial and unlikely to cause harm [36]. We will randomize at the level of the paramedic service, as individual-level randomization is not possible due to the inclusion of multiple, heterogeneous regions. Each site will serve as its own control. A site in this context may include more than one paramedic service. This study is a regional trial, with a focus on limited efficacy testing through an intermediate outcome (i.e., time to ROSC) that is strongly associated with survival [37]. Methods This protocol follows the SPIRIT reporting guidelines [38]. Study setting {9} Ontario is the most populous province in Canada, with an estimated population of 15.9 million in 2024 [39]. The incidence of POHCA in the province ranges from 4 to 9 cases per 100,000 person-years [6, 40]. This trial encompasses paramedic services operating in both rural and urban communities, allowing us to evaluate the intervention across different demographic contexts. Eligibility criteria {10} The enrollment of paramedic services was not limited by size or geographical coverage; however, providing land ambulance services was included as part of the eligibility criteria. The trial will include children aged 1 day to <18 years who experience an OHCA during the study period in the jurisdictions of participating paramedic services. The initial enrolment of study participants will be carried out by the paramedics at the scene, who will determine eligibility based on age and the presence of OHCA. The intervention will only be administered if the paramedics are working at a site that is currently under the intervention arm of the study. An OHCA will be defined as requiring more than 1 min of chest compressions, or defibrillation. It is important to note that paramedics are not to administer epinephrine if the child no longer requires chest compressions. We will exclude participants who experienced OHCA secondary to trauma as per the discretion of the attending paramedic. Patients who experience OHCA due to drowning or hanging will be included. In the unlikely event that a patient is enrolled more than once (e.g., if they experience more than one OHCA during the study period), we will model patient ID as a random effect to account for within-patient dependence. The study team will review the eligibility criteria for each enrolled participant, and any deviations will be reported to the Research Ethics Board (REB). Who will take informed consent? {26a} This trial requires timely implementation of the study intervention, and individual patient consent will not be feasible prior to treatment. We have, therefore, secured approval for a waiver of consent for children who do not survive and for those included in the retrospective control period of data collection. Additionally, we have obtained approval for deferred consent for survivors. Given that many children who survive may experience new and significant neurological impairments, we will not seek assent and will instead obtain consent from the child’s designated decision-maker (e.g., primary caregiver). The study coordinator will make up to three contact attempts to obtain consent. If consent is not obtained by the third attempt, only data collected up to that point will be used for the study; no additional data will be collected. Additional consent provisions for collection and use of participant data and biological specimens {26b} Not applicable, as this is not an ancillary study, and no biological samples will be collected. Interventions Explanation for the choice of comparators {6b} We will collect baseline data from each participating paramedic site with a lookback window of two years from the study start date. The baseline data will be included as part of the control period for each site, as there have been no significant changes to resuscitation guidelines with respect to epinephrine administration in the previous 2 years. The next set of resuscitation guidelines will be published in late 2025, and EMS-level changes are unlikely to be implemented prior to mid-2026. In addition to retrospective data, the control period for each site will also include prospective data, to be collected following the site’s entry into the study until the point at which it transitions into the intervention arm. In this way, each site will be able to serve as its own control for a minimum of 2 years and 2 months, up to 3 years and 10 months. If a site is in the control arm, Advanced Care Paramedics (ACPs) and Primary Care Paramedics (PCPs) must follow standard of care practices (i.e., Advanced Life Support Patient Care Standards) when responding to POHCA events [41]. The administration of epinephrine via IV/IO injection can be done by ACPs, but not PCPs (Fig. 1). IM epinephrine is considered standard of care in POHCA cases where anaphylaxis is suspected as the underlying cause, and it can be administered by ACPs or PCPs. The choice of comparator is justified as IV and IO epinephrine are well-supported by current clinical guidelines as standard practice in the management of POHCA. Flow diagram comparing care in the intervention and control arm. Abbreviations: POHCA, pediatric out-of-hospital cardiac arrest; AED, automated external defibrillator; SOC, standard of care; IV, intravenous; IO, intraosseous; IM, intramuscular; ACP, advanced care paramedic; PCP, primary care paramedic Intervention description {11a} When a site is in the intervention arm, ACPs and PCPs will follow standard of care until the point of administering the first dose of epinephrine. The initial dose of epinephrine in the intervention arm will be delivered via the IM route by ACPs or PCPs, depending on who arrives first at the scene. This initial dose will be delivered using a pre-filled syringe, with dosing determined using a study-specific length-based tape (Fig. 2). The dosing schedule is based on patient weight and IM epinephrine bioavailability (Table 1). The IM injection will be delivered to the patient’s anterolateral thigh, based on prior research indicating greater IM epinephrine bioavailability at this site compared with the upper arm [42]. Following the initial dose of IM epinephrine, ACPs will administer a dose of IV/IO epinephrine as soon as possible, with subsequent IV/IO doses administered in 3- to 5-min intervals, as per standard of care. Study length-based dose selection tape (not to scale) Table 1Study intramuscular epinephrine dosing scheduleWeight (kg)Dose (mg) ≥3 to <50.3 ≥5 to <100.5 ≥10 to <201 ≥20 to <302 ≥303 Study intramuscular epinephrine dosing schedule In our dosing schedule, we recommend the IM epinephrine dose be up to 10 times higher than the corresponding IV dose for a child of equivalent weight [27–29]. The IM dose may only achieve up to a similar level of potency as the IV dose if it is optimally absorbed and circulated in the bloodstream. This dosing regimen was informed by human pharmacokinetic data of IM epinephrine [27–29], prior pediatric cardiac arrest animal studies of IM epinephrine [32, 43], and an adult OHCA IM epinephrine feasibility study [34]. Epinephrine storage and monitoring Storage instructions per product monograph indicate that epinephrine be kept at room temperature (between 15 and 30 °C) to maintain safety and effectiveness. The temperature of study packages containing epinephrine will be tracked using TempTale® USB data loggers, which will record temperature changes during shipment from the compounding company to the lead site (Children’s Hospital - London Health Sciences Centre) and from the lead site to designated paramedic services. The temperature will not be monitored following shipment receipt by the paramedic service, as all ambulances are equipped with temperature control systems. Any temperature excursions will be assessed by the lead site to ensure product safety. Only major excursions meeting criteria for reportable events will be reported to the REB. Criteria for discontinuing or modifying allocated interventions {11b} The safety profile of IM epinephrine is well established, and it is considered standard of care in cases of POHCA where the suspected etiology is anaphylaxis. Therefore, there are no criteria for discontinuing or modifying the intervention protocol for trial participants. Strategies to improve adherence to interventions {11c} We will support protocol adherence by providing paramedic services with regular updates on the intervention protocol, including answers to frequently asked questions, training videos, information sessions, and any other resources necessary for sites transitioning to the intervention arm of the study. Relevant concomitant care permitted or prohibited during the trial {11d} There will be no restrictions on concomitant care. Paramedics are follow the standard of care when administering additional medications, fluids, or other treatments as required. Provisions for post-trial care {30} In cases where further medical care is required, trial participants will be transported by ambulance to a nearby medical facility for continued management and treatment. Outcomes {12} The primary outcome is time to ROSC, which will be measured from the time paramedics arrive at the patient’s side, or from the time of arrest for paramedic-witnessed cases. We will assess the following secondary outcomes: presence of ROSC; presence and time to sustained ROSC; survival to hospital admission; length of stay in the pediatric critical care unit (PCCU); hospital length of stay; survival to hospital discharge; survival at 6 and 12 months post-POHCA; neurological status at hospital discharge; neurological status at 6 and 12 months post-POHCA; and life impact at 6 and 12 months post-POHCA. We will assess life impact using the Pediatric Quality of Life Inventory (PedsQL). We will also report the time to definitive epinephrine dose (i.e., IV or IO). We will assess protocol adherence by determining the rate of IM epinephrine administration in eligible POHCA events. Participant timeline {13} Patients will be screened for eligibility at the time of the event by the paramedics at the scene (Fig. 3). If the patient is eligible for the trial, the attending paramedics will follow either the intervention protocol (first dose of IM epinephrine followed by standard of care) or control protocol (standard of care) depending on the current assignment of their paramedic service. The following outcomes will be assessed by the paramedics at the scene: presence of ROSC; time to ROSC; presence of sustained ROSC; time to sustained ROSC. If applicable, we will assess survival at the following time points: hospital admission; transfer from emergency department to the PCCU; hospital discharge; and at 6 and 12 months post-event. PCCU and hospital length of stay will be assessed at the time of hospital discharge, if applicable. Neurological status for surviving patients will be assessed at the time of hospital discharge and at 6 and 12 months post-event. Life impact will be assessed using the PedsQL at 6 and 12 months post-event. Adverse events will be identified by attending paramedics at the scene or through a review of hospital records for patients admitted to the lead site: London Health Sciences Centre (LHSC). Participant timeline (SPIRIT diagram). Abbreviations: EMS, emergency medical services; POHCA, pediatric out-of-hospital cardiac arrest; SOC, standard of care; IM, intramuscular; IV, intravenous; IO, intraosseous; ROSC, return of spontaneous circulation; ED, emergency department; PCCU, pediatric critical care unit; PedsQL, Pediatric Quality of Life Inventory; LHSC, London Health Sciences Centre Sample size {14} We accounted for cluster size and design effect in our sample size calculation [44]. Based on an average time to ROSC of 23 min (standard deviation = 13.12) for POHCA patients treated by a large urban paramedic service in our region (Middlesex-London Paramedic Services), we require a sample size of N = 86 patients (n = 43 per group) who achieve ROSC to have 80% probability of detecting a difference in time to ROSC of 8 min or greater between the control and intervention arms. This calculation is based on a sample size calculation with α = 0.05 (two-sided), 1−β = 0.8, average cluster size of n = 3 POHCA events, 1% intra-cluster correlation coefficient, and variation in site sizes [45]. Previous data from local and nation-wide sample indicate that approximately 30% of POHCA patients achieve ROSC; thus, we require a total sample size of 288 POHCA patients. The control period will include 2 years of historical data (anticipated n = 96). We have also reviewed the number of eligible POHCA events observed in our region over the last 4 years and found that our sample size calculation is similar to the predicted convenience sample across all participating services for the 4-year study period. Recruitment {15} We aim to reach our target sample size by enrolling as many paramedic services as our budget allows and by educating paramedics effectively and regularly to ensure that no potential participants are missed. Assignment of interventions: allocation Sequence generation {16a} We randomized sites on a staggered schedule, with one site entering the intervention arm every 2 months (Table 2). Once a site transitions to the intervention arm, it will remain there for the duration of the study (i.e., any POHCA patients encountered by paramedics in that jurisdiction should be treated according to the intervention protocol). Due to considerable heterogeneity in service size, we randomized larger sites (i.e., those with more than five POHCAs per year, based on historical records) independently of other sites to ensure balance in study arms (i.e., quasi-randomization). The sites were randomized using an online application (Sealed Envelope, London, UK). The duration of time that a site spends in the control vs. intervention arm varies by their randomization block. Table 2Randomization plan.TimeBLOCKMonth 0Month 2Month 4Month 6Month 8Month 10Month 12Month 14Month 16Month 18Month 20Month 22Years 3 & 4Site 10111111111111Site 20011111111111Site 30001111111111Site 40000111111111Site 50000011111111Site 60000001111111Site 70000000111111Site 80000000011111Site 90000000001111Site 100000000000111Site 1100000000000110 = prospective control period, 1 = intervention period Randomization plan. 0 = prospective control period, 1 = intervention period The prospective data collection period will span a total of 4 years with an additional 1 year for follow-up on long-term outcomes among survivors. The prospective control period for a site will only begin once all enrollment procedures have been completed (i.e., ethics approvals and data sharing agreements). This date may differ between sites, as enrollment is ongoing. If additional sites enroll after the trial start date, their historical control period will include the 2 years directly preceding the trial start date, as well as any cases encountered since the trial start date. These additional sites will adhere to the established randomization order if they enroll prior to Month 21, at which point most sites would have already entered the intervention period (per the randomization schedule). Sites entering the trial prior to Month 21 will (a) be assigned to the next available site position in the established randomization order, or (b) be randomly assigned to one of the remaining available site positions. For example, per Table 1, if a site chooses to participate in the trial at Month 8, possible site selections include site numbers 5 through 11. Sites entering the trial beyond Month 21 will not be included in the established randomization order but could be considered separately for per-protocol analysis. Concealment mechanism {16b} Participating paramedic sites will be made aware of their intervention arm entry date prior to enrolling in the trial. Implementation {16c} The randomization schedule was developed by the study biostatistician using an online application (Sealed Envelope, London, UK). The initial enrolment of participants will be completed by the paramedics at the scene. The attending paramedics will follow the intervention protocol if their site is currently under the intervention arm of the trial. Assignment of interventions: blinding Who will be blinded {17a} This trial is unblinded due to its clustered design and the emergency setting of the intervention. Procedure for unblinding if needed {17b} Not applicable, as this trial is unblinded. Data collection and management Plans for assessment and collection of outcomes {18a} We will collect data from ambulance call reports, emergency department records and inpatient records (where applicable). We will also collect post-discharge and follow-up data for survivors. We will conduct follow-up phone call visits with enrolled participants’ parents or guardians at two time points (i.e., 6 and 12 months post-POHCA) to assess neurological and life impacts, and document any adverse events. Plans to promote participant retention and complete follow-up {18b} We will promote retention among surviving participants by making up to three contact attempts to the child’s designated caregiver. If consent to participate is not obtained by the third attempt, only data collected up to that point will be used for the study; no additional data will be collected. Data management {19} The data will be securely stored using the Research Electronic Data Capture (REDCap) application at London Health Sciences Centre Research Institute (formerly known as the Lawson Health Research Institute). REDCap is a secure, web-based platform designed to facilitate the management of clinical research databases [46]. It incorporates multiple strong security features to prevent unauthorized access to patient data, including an internal table-based authentication method to verify the passwords of all users. The system also enforces password changes every 6 months, limits password reuse, and includes an auto logout feature. Additionally, REDCap uses real-time validation rules to ensure data quality, including automated checks for data types and ranges at the time of entry. Confidentiality {27} The datasets generated on REDCap will only be accessible by members of the research team, with user privileges being designated by the study coordinator to ensure that each member has only the minimum required rights to perform their duties. All identifying information that is collected will be flagged in REDCap and removed from data export unless required for statistical analysis. Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use {33} Not applicable, as biological specimens will not be collected as part of this study. Statistical methods Statistical methods for primary and secondary outcomes {20a} We will first analyze the data on an intention-to-treat basis, followed by a per-protocol analysis to assess the impact of the intervention under both practical and ideal conditions. The intention-to-treat analysis will classify patients according to the protocol they were assigned to receive (i.e., based on whether the attending paramedic service was in the control or intervention arm of the study), irrespective of any protocol deviations (e.g., a patient treated by a paramedic service under the intervention arm but who mistakenly received the control protocol will still be analyzed as an intervention patient). The per-protocol analysis will classify patients according to the protocol they received, irrespective of assignment (e.g., a patient treated by a paramedic service under the intervention arm but who mistakenly received the control protocol will be analyzed as a control patient). Descriptive statistics will be used to assess differences in baseline characteristics between the control and intervention arms (Suppl. Table 1). Categorical variables will be summarized using frequencies and proportions. Continuous variables will be summarized using means and standard deviations (or medians and interquartile ranges for non-normal distributions). A linear mixed-effects model will be used to compare mean differences in the primary outcome of time to ROSC between the control and intervention arms (fixed effects), while simultaneously accounting for similarities in service sites (random effect using a variance components covariance structure with random intercept). This will serve as the primary analysis of time to ROSC and will include only patients who achieved ROSC (i.e., there will be no censored data). Compared to other analyses (e.g., cluster-level analyses), mixed-effect models simplify the examination of possible interaction effects, are flexible in terms of imbalances in study design, and directly account for dependence in the data [44, 47]. In addition to the primary analysis of time to ROSC using a linear mixed-effects model, we will also conduct a secondary analysis of this outcome using a cause-specific Cox proportional hazards model (and/or a Fine-Gray subdistribution hazards model, as necessary). This analysis will classify death as a competing event; differences in follow-up time will not be a concern as time to ROSC will be measured similarly for all patients - from a fixed starting point (the time of arrest) to a definite endpoint (ROSC). Linear and generalized mixed-effects models will be used to compare secondary outcomes between the two study arms. We will use linear (or Poisson, as appropriate) mixed-effects models to assess time to sustained ROSC, PCCU length of stay, hospital length of stay, and life impact post-POHCA. We will use generalized mixed-effects logistic regression models to assess binary outcomes including presence of ROSC, presence of sustained ROSC, survival to hospital admission, survival to hospital discharge, survival post-POHCA, and neurological status at hospital discharge, and neurological status post-POHCA. All statistical models will include the outcome of interest, a fixed-effect variable for group (control vs. intervention), and a random-effect variable for service site modeled using a simple variance components covariance structure with random intercept. No additional covariates will be included. We acknowledge the possibility of multiplicity for secondary outcomes; however, these analyses are exploratory and without specific hypotheses. The sample size has been set to ensure adequate power for the primary outcome. SPSS version 30 (IBM Corp., Armonk, NY, USA) will be used for all analyses, and p-values < 0.05 will be considered statistically significant. Interim analyses {21b} We will conduct an interim analysis of the primary outcome once we have recruited 50% of our required sample size. The study sample for this initial analysis will likely be imbalanced, with a higher proportion of control patients due to the inclusion of historical controls and the staggered start of the intervention across sites. We will conduct an additional interim analysis once we have recruited 75% of our required sample size, at which point the sample in both arms is expected to be more balanced. The study investigators will be blinded to the results of the interim analysis. The findings will only be accessible to members of the Data Safety and Monitoring Board (DSMB), an independent group of experts assigned to the study. The DSMB will review the interim analysis and provide recommendations regarding study progress and safety, with particular attention to the incidence of adverse and serious adverse events in both study arms, time to definitive dose of epinephrine, and feasibility of study drug administration. The DSMB will also assess recruitment rates, protocol adherence, and data management quality. There are no pre-defined stopping rules for this trial. Methods for additional analyses (e.g., subgroup analyses) {20b} For exploratory purposes, a sensitivity analysis will examine primary and secondary outcomes excluding infants classified with a very low likelihood of survival (i.e., infants discovered after a period of sleep with asystole as the initial and only rhythm during resuscitation). Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c} We do not anticipate missing data for the group or service site variables. However, missing data for primary and secondary outcomes will not be imputed to uphold statistical integrity of the outcomes of interest and keep potential bias to a minimum. Plans to give access to the full protocol, participant level-data and statistical code {31c} The full protocol is attached as a supplementary document. The participant-level dataset will not be made publicly available to maintain participant confidentiality. The corresponding author may grant access to a de-identified version of the data upon request. Similarly, the statistical code will not be made publicly available but may be provided by the corresponding author upon request. Oversight and monitoring Composition of the coordinating centre and trial steering committee {5d} The coordinating centre is comprised of a team of experienced clinicians, academics and research staff responsible for overseeing trial conduct and managing day-to-day operations. The team maintains regular communication and provides ongoing updates about the trial; meeting as needed to support shared decision-making and respond to any emerging issues. Composition of the data monitoring committee, its role and reporting structure {21a} The Data Safety Monitoring Board (DSMB) for this study is comprised of two clinicians and a biostatistician. The DSMB will have access to the interim analysis findings and receive regular updates on study progress including recruitment, and the occurrence of any adverse events. The DSMB functions independently from the study investigators and can recommend a review of the study design or request protocol re-evaluation based on the findings of the interim analysis or if the proportion of adverse events becomes significantly unbalanced between the two groups. The DSMB will meet to review the findings from the interim analysis and will meet thereafter on an as-needed basis. Adverse event reporting and harms {22} The research team will review ambulance call reports and patient medical records (for patients admitted to London Health Sciences Centre) for any adverse events. Adverse events to be reported include those that are plausibly associated with the receipt of IM epinephrine, and those that deviate from the expected clinical course or natural history of POHCA, such as necrotizing fasciitis, a rare complication that has been documented in case reports [48, 49]. Any serious adverse event that meets these criteria and indicates an increased risk of harm to research participants or others beyond what was previously known or recognized will be promptly reported to the DSMB, the REB and Health Canada. Frequency and plans for auditing trial conduct {23} The trial may be subject to routine or for-cause audits by Health Canada or other regulatory authorities to assess site compliance with the protocol and regulatory requirements. These audits operate independently from the study investigators and the sponsor. Plans for communicating important protocol amendments to relevant parties (e.g., trial participants, ethical committees) {25} Any amendments to the protocol or participant-facing materials will be reviewed and approved by the REB prior to being implemented in the study. Dissemination plans {31a} We aim to communicate trial findings with all relevant stakeholders. The study team will prepare research presentations and manuscripts, with authorship determined by significant contributions to the study’s design, implementation, data analysis, or manuscript preparation and review. If the study yields positive results, we also intend to compile a report for industry representatives that will serve as a tool to improve autoinjector dosing and access for paramedic services. Discussion IM epinephrine may provide a more efficient delivery for the initial dose of epinephrine in children experiencing OHCA, potentially leading to improved short- and long-term outcomes for these patients. Previous literature details the safety profile of IM epinephrine for anaphylaxis management [23–25]. These data suggest that IM epinephrine presents no greater risk compared to the standard of care in POHCA. The findings from a prior animal study suggest a potential for improved outcomes with early IM epinephrine relative to delayed IV epinephrine [32]. Similarly, a recent study by Palatinus et al. (2024) indicates an association between IM epinephrine and improved survival and neurological outcomes in adult OHCA patients [35]. However, notable gaps remain in human research on the effectiveness of IM epinephrine in POHCA. This multi-site SW-CRCT aims to help address this gap by evaluating the impact of IM epinephrine on time to ROSC in this population. There are several factors to consider when exploring the use of IM epinephrine in POHCA. Human pharmacokinetic data highlight the differences in peak plasma concentration and time to peak plasma concentration for IM vs. IV or IO routes of administration. IM epinephrine peaks approximately 5–15 min following injection, and the peak plasma concentration is lower than that expected from an equivalent dose of IV epinephrine [26–30]. These data helped inform the dosing schedule for the PRIME trial, which includes IM doses that are between 5 and 10 times greater than the corresponding IV doses for a child of equivalent weight, with an aim of achieving comparable bioavailability. In the intervention arm of the PRIME trial, paramedics will secure vascular access and administer the definitive dose of epinephrine (IV/IO) as soon as possible following the IM injection. We will track and report time to definitive dose of epinephrine (IV/IO) for both the control and intervention arms. The time to maximum concentration for the IM dose may coincide with the time to maximum concentration for the IV/IO dose. If this happens, the patient could potentially receive up to double the recommended dose of epinephrine at one time. Perondi et al. (2004) evaluated the impact of a 10 times higher dose of epinephrine on pediatric in-hospital cardiac arrest, finding no benefit but a trend towards harm [50]. However, recent data indicate that shortened dosing intervals (i.e., less than 2 min as opposed to 3 to 5 min) are associated with improved outcomes in pediatric cardiac arrest [51]. These data suggest that there is minimal risk of harm associated with administering a double dose of epinephrine. The PRIME trial will use pre-filled syringes for IM epinephrine delivery. Pre-filled syringes are similar to autoinjectors in that they eliminate the need to measure and draw up the study drug. This approach may shorten time to first dose compared to IV/IO administration, which require paramedics to draw up the medication and secure vascular access. We recently conducted a simulation trial of POHCA to measure differences in time to epinephrine across different administration approaches. The study found a significantly shorter median time to first dose of 1 min 26 s (p-value < 0.001) with IM autoinjectors (i.e., pre-filled epinephrine) compared with IV/IO injections which require drug preparation at the time of administration [52]. It is also important to note that epinephrine autoinjectors are most commonly available at 0.3 mg dosing. The findings from the PRIME trial may identify a need for epinephrine autoinjectors with expanded dosing ranges. Trial status The current protocol version is dated December 17, 2025. Prospective patient recruitment began in January 2024 and will continue until January 2028. As of December 30, 2024, we have recruited a total of 139 patients: 3 in the intervention group, 25 in the prospective control group, and 111 in the retrospective control group. Supplementary Information Supplementary Material 1. Acknowledgements We are sincerely grateful to each participating paramedic service for their ongoing support and dedication to this research. We extend our thanks to Trio Compounding Lab and Pharmacy, for supplying the medication packages and pre-filled syringes, Sol-Millennium Medical Group for contributing the corresponding needles, and Eagle Analytical Services for method validation testing of the pre-filled syringes for sterility, potency, and stability. Abbreviations Pediatric-out-of-hospital cardiac arrest Intravenous Intraosseous Intramuscular Pediatric Out-of-Hospital Cardiac Arrest Resuscitation: Evaluation of IM Epinephrine Return of spontaneous circulation Cardiopulmonary resuscitation Automated external defibrillator Emergency medical services Pediatric Advanced Life Support Out-of-hospital cardiac arrest Stepped-wedge cluster randomized controlled trial Research Ethics Board Clinical Trials Ontario Advanced care paramedic Primary care paramedic Research Electronic Data Capture Data safety monitoring board London Health Sciences Centre Authors’ contributions {31b} JAT is the principal investigator; she conceptualized the study, led protocol development, and was a major contributor to manuscript review and editing. MA is the lead study coordinator; she outlined the study protocol, managed research activities across multiple sites, and was a major contributor to manuscript review and editing. SI contributed to the study design, coordinated research activities, and led manuscript development and revision. MD, FG-B, and JL provided clinical expertise, contributed to protocol development, coordinated research activities, and reviewed and edited the manuscript. MM is the trial biostatistician; he developed the statistical analysis plan and randomization strategy, drafted the statistical analysis section of the paper, and reviewed and edited the final manuscript. All authors read and approved the final manuscript. Funding {4} This study is funded by the Academic Medical Organization of Southwestern Ontario, the Children's Health Research Institute, the Thrasher Research Fund, and the Heart and Stroke Foundation of Canada. The funding agencies had no influence in the conceptualization, design, conduct, analysis or publication of this study. Data availability {29} The final trial dataset will not be made publicly available to maintain participant confidentiality; however, access to a de-identified version may be provided by the corresponding author upon request. Declarations Ethics approval and consent to participate {24} We have obtained ethics approval from Clinical Trials Ontario (CTO). CTO hosts a streamlined ethics review service to enable multi-site trials to proceed with a single ethics application and approval. The Western University Health Sciences Research Ethics Board (HSREB) serves as the designated CTO Qualified REB for this study. We have received REB approval (CTO #4518) for the study including the protocol and all participant-facing materials (e.g., consent forms, recruitment documents). This trial requires timely implementation of the study intervention, and individual patient consent will not be feasible prior to treatment. We have secured approval for a waiver of consent for children who do not survive and for those included in the retrospective control period of data collection. Additionally, we have obtained approval for deferred consent for survivors. Given that many children who survive may experience new and significant neurological impairments, we will not seek assent and will instead obtain consent from the child’s designated decision-maker (e.g., primary caregiver). Consent for publication {32} Not applicable, as we do not intend to publish any identifiable patient information. Competing interests {28} The authors have no competing interests to disclose. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The final trial dataset will not be made publicly available to maintain participant confidentiality; however, access to a de-identified version may be provided by the corresponding author upon request.